Clindamycin Hydrochloride for Injection

Pharmacological action: This product is a lincosamide antibiotic that mainly binds to the 50S subunit bacterial ribosome, inhibits early bacterial protein synthesis, removes the A protein and villi coat on the bacterial surface, and makes it easy to be phagocytosed and killed. In vitro tests show that clindamycin is active against the following microorganisms: 1. Aerobic Gram-positive cocci: Staphylococcus aureus and Staphylococcus epidermidis (both penicillinase-producing and non-penicillinase-producing strains), Streptococci (except Enterococcus faecalis), and Pneumococci. 2. Anaerobic Gram-negative rods: Bacteroides (including Bacteroides fragilis and melanin-producing Bacteroides) and Fusobacterium. 3. Anaerobic Gram-positive non-spore-producing rods: Propionibacterium, Eubacterium, and Actinomyces. 4. Anaerobic and microaerophilic Gram-positive rods: Peptococcus, microaerophilic Streptococcus, and Peptostreptococcus. Toxicological studies: Genetic toxicity: The results of the Ames Salmonella reverse mutation test and the rat micronucleus test were negative. Reproductive toxicity: The oral dose of this product to rats was 300 mg/kg, and no effect on animal mating and fertility was observed. Rats and mice were given clindamycin at a dose of up to 600 mg/kg orally or 250 mg/kg subcutaneously, and no teratogenic effect was observed. However, there are no sufficient and rigorous clinical studies on pregnant women, and animal reproductive studies cannot fully predict human responses. This product can only be used during pregnancy when it is clearly needed. Preparation safety test: The results of animal muscle irritation tests show that this product can cause severe congestion and muscle degeneration in the quadriceps of rabbits after intramuscular injection.

Clindamycin hydrochloride.

This product is white or off-white loose mass or amorphous solid.

The following infectious diseases caused by Gram-positive bacteria: 1. Tonsillitis, suppurative otitis media, sinusitis, etc. 2. Acute bronchitis, acute exacerbation of chronic bronchitis, pneumonia, lung abscess and bronchiectasis combined infection, etc. 3. Skin and soft tissue infections: furuncle, sore, abscess, cellulitis, trauma, burns and surgical infection, etc. 4. Urinary system infection: acute urethritis, acute pyelonephritis, prostatitis, etc. 5. Others: myelitis, sepsis, peritonitis and oral infection, etc. Various infectious diseases caused by anaerobic bacteria: 1. Empyema, muscle abscess, anaerobic pneumonia. 2. Skin and soft tissue infection, sepsis. 3. Intraperitoneal infection: peritonitis, intraperitoneal abscess. 4. Female pelvic and genital infections: endometritis, non-gonococcal fallopian tube and ovarian abscess.

Adults: deep intramuscular injection or intravenous drip. Moderate infection: 0.6~1.2g/day, divided into 2~3 times. Severe infection: 1.2~2.7g/day, divided into 2~3 times. Or as directed by a doctor. Children: intramuscular injection or intravenous drip. Moderate infection: 15~25mg/kg/day, divided into 2~3 times. Severe infection: 25~40mg/kg/day, divided into 2~3 times. Or as directed by a doctor. Intravenous drip: dilute 0.3g of this product with 100ml of normal saline or 5% glucose solution and drip intravenously for 30 minutes.

1 Local reaction: After intramuscular injection, slight pain may occasionally occur at the injection site. Long-term intravenous infusion should pay attention to the occurrence of phlebitis. 2 Gastrointestinal reactions: Occasionally, nausea, vomiting, abdominal pain and diarrhea may occur. 3 Allergic reactions: A small number of patients may develop drug-induced rashes. 4 There is basically no toxic reaction to the hematopoietic system. It may occasionally cause neutropenia, eosinophilia, thrombocytopenia, etc., which are generally mild and transient. 5 A small number of patients may experience transient alkaline phosphatase, mild elevation of serum transaminases and jaundice. 6 A very small number of patients may develop pseudomembranous colitis.

This product has cross-resistance with lincomycin and is contraindicated in patients with a history of allergy to this product or lincomycin.

Precautions for children: The efficacy and safety of the drug for children under 12 years old have not been established. Precautions for pregnancy and lactation: The efficacy and safety of the drug for pregnant women have not been established, and this product can pass through the placenta, so pregnant women should use it with caution; this product can be secreted into breast milk, so lactating women should use it with caution. If this product must be used, breastfeeding should be suspended. Precautions for the elderly: The efficacy and safety of the drug for elderly patients over 65 years old have not been established. Elderly people with serious underlying diseases are prone to adverse reactions such as diarrhea or pseudomembranous colitis, and need to be closely observed when taking the drug.

1. This product can enhance the neuromuscular blockade of inhaled anesthetics, leading to skeletal muscle weakness and respiratory depression or paralysis (apnea). Caution should be taken when used in combination during or after surgery. Treatment with anti-basic esterase drugs or calcium salts is expected to be effective. 2. This product can cause pseudomembranous colitis with severe watery diarrhea during or even weeks after the course of treatment when used in combination with antiperistaltic antidiarrheal drugs and antidiarrheal drugs containing white clay. Because it can delay the excretion of colonic endotoxins, leading to prolonged and aggravated diarrhea, this product should not be used in combination with antiperistaltic antidiarrheal drugs. When used in combination with antidiarrheal drugs containing white clay, the absorption of this product will be significantly reduced, so the two should not be taken at the same time, and a certain interval (at least 2 hours) is required. 3. This product has a neuromuscular blocking effect and can enhance the effect of neuromuscular blocking drugs. The two should be avoided in combination. When this product is used in combination with anti-myasthenic drugs, the latter will weaken the effect on skeletal muscles. In order to control the symptoms of myasthenia gravis, the dose of anti-myasthenic drugs should be adjusted when used in combination. 4 Chloramphenicol or erythromycin can replace this product at the target site, or inhibit the binding of this product to the bacterial ribosome 50S subunit. In vitro tests show that this product has an antagonistic effect with erythromycin, so this product should not be used in combination with chloramphenicol or erythromycin. 5 When used in combination with opioid analgesics, the respiratory depression of this product and the central respiratory depression of opioids may add up to prolong respiratory depression or cause respiratory paralysis (apnea), so patients must be closely observed or monitored. 6 This product should not be added to infusions with complex components to avoid incompatibility.

Keep tightly closed.

0.3g (calculated as C18H33ClN2O5S)

24 months

Guangzhou Yipinhong Pharmaceutical Co., Ltd.

• Founded in:

  2010-07-16

• Address:

  No. 6 Dongbo Road, East District, Guangzhou Economic and Technological Development Zone

• Tax NO.:

  914401015583834183

• Registered Funds:

  50 million yuan

• Website:

  Log in to view

• Email:

  Log in to view